DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS | Real-time Bid/Ask 09:57:08 2024-07-16 EDT | ||
| 2.76 EUR / 2.9 EUR | +4.04% |
|
| 1 month | -1.81% | ||
| 3 months | +36.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 2.76 | +1.47% |
| 24-07-15 | 2.72 | +0.74% |
| 24-07-12 | 2.7 | -4.93% |
| 24-07-11 | 2.84 | 0.00% |
| 24-07-10 | 2.84 | 0.00% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 05:45 am
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG0D7A |
| ISIN | DE000MG0D7A8 |
| Date issued | 2024-03-18 |
| Strike | 250 $ |
| Maturity | 2025-03-21 (248 Days) |
| Parity | 10 : 1 |
| Emission price | 2.23 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.04 € |
|---|---|
| Lowest since issue | 1.35 € |
| Spread | 0.16 € |
| Spread % | 5.44% |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
280
USD
Average target price
365.3
USD
Spread / Average Target
+30.50%
- Stock Market
- Certificates
- Certificat
